This association was observed mainly in patients with HER2+ BC (21.5% vs. 9%; p = 0.015) and, among those with high levels of LEPR, in patients who achieved a complete pathological response compared to those with residual disease (26.6% vs. 12.5%; p = 0.005) whereas this imbalance was not observed in patients with the LEPR not overexpressed [78]. Here, ERBB2 is linked to breast cancer.